Key Takeaways JNJ has traded above its 50- and 200-day SMAs since June, with a golden cross formed in mid-July.J&J's Innovative Medicine unit delivered organic growth in 2025 despite Stelara's loss of exclusivity.JNJ advanced its pipeline with new approvals and launches, while MedTech showed signs of recovery.Johnson & Johnson’s (JNJ) stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since the end of June. It achieved the golden cross in mid-July. The 50-day movi ...